Outlook Therapeutics Inc (NAS:OTLK)
$ 1.805 -0.225 (-11.08%) Market Cap: 42.70 Mil Enterprise Value: 48.72 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 34/100

Q3 2024 Outlook Therapeutics Inc Earnings Call Transcript

Aug 14, 2024 / 12:30PM GMT
Release Date Price: $7.34 (-5.29%)
Operator

Greetings, and Welcome to the Outlook Therapeutics corporate third-quarter fiscal year 2024 update conference call and webcast. (Operator Instructions)

It is now my pleasure to introduce your host, Jenene Thomas, Investor Relations. Thank you. Please go ahead.

Jenene Thomas
JTC IR - IR

Thank you, Donna.

At this time, I'd like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations or future projections, including, but not limited to, our expectations about the timing of clinical trials and commercial launch and the sufficiency of our cash resources. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws and are based on Outlook Therapeutics current expectations, and actual results could differ materially.

As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot